Format

Send to

Choose Destination
Dig Dis Sci. 2019 May;64(5):1079-1088. doi: 10.1007/s10620-019-05526-5.

Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA.

Author information

1
Department of Internal Medicine, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
2
Division of Gastroenterology and Hepatology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. billa17@hotmail.com.
3
Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, 1200 East Broad Street, P.O. Box 98034, Richmond, VA, 23298, USA.
4
Division of Gastroenterology and Hepatology, University of Virginia, P.O. Box 800708, Charlottesville, VA, 22908, USA.

Abstract

Gastric intestinal metaplasia (GIM) is a premalignant condition that can lead to intestinal-type gastric adenocarcinoma. It is characterized by a change in the gastric mucosa to a small-intestinal phenotype. Infection with Helicobacter pylori is the most common factor associated with GIM. Although GIM is typically a histologic diagnosis, various techniques have been developed to enable the endoscopic identification of GIM. There are presently no widely accepted guidelines on screening and surveillance strategies in patients with GIM in the USA. The aim of this review is to provide an update regarding the problem, diagnosis, and management of GIM in the USA.

KEYWORDS:

Early gastric cancer; Gastric adenocarcinoma; Gastric intestinal metaplasia; Helicobacter pylori

PMID:
30771043
DOI:
10.1007/s10620-019-05526-5

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center